EANM/SNMMI guideline for 18F-FDG use in inflammation and infection

Journal of Nuclear Medicine

Volumn 54, Issue 4, 2013, Pages 647-658

  Jamar, Francois ^a   Buscombe, John ^b   Chiti, Arturo ^c   Christian, Paul E ^d   Delbeke, Dominique ^e   Donohoe, Kevin J ^f   Israel, Ora ^b   Martin Comin, Josep ^g   Signore, Alberto ^h  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Cambridge Biomedical Campus ^*  (Israel)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF UTAH   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CELL DAMAGE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC FOOT; DRUG UPTAKE; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; GLUCOSE INTAKE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; INFECTION; INFLAMMATION; JOINT PROSTHESIS; MEDICAL SOCIETY; NONHUMAN; OSTEOMYELITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHESIS INFECTION; PYREXIA IDIOPATHICA; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SPONDYLITIS; VASCULITIS;

BREAST FEEDING; DOCUMENTATION; FEMALE; FLUORODEOXYGLUCOSE F18; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INFECTION; INFECTION CONTROL; INFLAMMATION; MOLECULAR IMAGING; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREGNANCY; QUALITY CONTROL; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RESEARCH REPORT; SAFETY; SOCIAL CONTROL, FORMAL; SOCIETIES, SCIENTIFIC;

EID: 84875779354     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112524     Document Type: Article

References (140)

1. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551-1555.
2. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
3. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
4. Gamelli RL, Liu H, He LK, Hofmann CA. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol. 1996;59:639-647.
5. Fukuzumi M, Shinomiya H, Shimizu Y, Ohishi K, Utsumi S. Endotoxin-induced enhancement of glucose influx into murine peritoneal macrophages via GLUT1. Infect Immun. 1996;64:108-112.
6. Mortimer JE, Dehdashti F, Siegal BA, et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803.
7. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumor PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
8. 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885-895.
9. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;35:1537-1543.
10. 18F-FDG PET/CT features. J Neuroradiol. 2010;37:172-181.
11. 18F-FDG PET. Q J Nucl Med Mol Imaging. 2011;55:66-71.
12. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009;36:1131-1137.
13. Mostard RL, Vöö S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011;105:1917-1924.
14. 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989-1998.
15. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med. 1998;39:1160-1166.
16. de Winter F, van de Wiele C, Vogelaers D, de Smet K, Verdonk R, Dierckx RA. Fluorine-18 fluorodeoxyglucose-position emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections. J Bone Joint Surg Am. 2001;83-A:651-660.
17. Guhlmann A, Brecht-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology. 1998;206:749-754.
18. 99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med. 1998;39:2145-2152.
19. 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis. Eur J Nucl Med Mol Imaging. 2007;34:704-714.
20. Hakim SG, Bruecker CW, Jacobsen HCh, et al. The value of FDG-PET and bone scintigraphy with SPECT in the primary diagnosis and follow-up of patients with chronic osteomyelitis of the mandible. Int J Oral Maxillofac Surg. 2006;35:809-816.
21. 18F-FDG imaging with a dual-head coincidence camera and 111In-labelled autologous leucocyte scintigraphy. Eur J Nucl Med Mol Imaging. 2002;29:53-60.
22. Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med. 2000;27:822-832.
23. Zhuang H, Duarte PS, Pourdehand M, Shnier D, Alavi A. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin Nucl Med. 2000;25:281-284.
24. De Winter F, Gemmel F, Van De Wiele C, Poffijn B, Uyttendaele D, Dierckx R. 18-fluorine fluorodeoxyglucose positron emission tomography for the diagnosis of infection in the postoperative spine. Spine (Phila Pa 1976). 2003;28:1314-1319.
25. 18F-FDG hybrid PET in patients with suspected spondylitis. Eur J Nucl Med Mol Imaging. 2002;29:516-524.
26. Schmitz A, Risse JH, Textor J, et al. FDG-PET findings of vertebral compression fractures in osteoporosis: preliminary results. Osteoporos Int. 2002; 13:755-761.
27. Schmitz A, Risse JH, Grünwald F, Gassel F, Biersack HJ, Schmitt O. Fluorine- 18 fluorodeoxyglucose positron emission tomography findings in spondylodiscitis: preliminary results. Eur Spine J. 2001;10:534-539.
28. Stumpe KD, Zanetti M, Weishaupt D, Hodler J, Boos N, Von Schulthess GK. FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR imaging. AJR. 2002;179:1151-1157.
29. 18F-FDG PET-CT: a proposal of diagnostic algorithm. Rev Esp Med Nucl. December 5, 2011 [Epub ahead of print].
30. Bleeker-Rovers CP, Vos FJ, Mudde AH, et al. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging. 2007;34:694-703.
31. Bleeker-Rovers CP, de Kleijn EM, Corstens FH, van der Meer JW, Oyen WJ. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging. 2004;31:29-37.
32. 18F-FDG PET in detecting metastatic infectious disease. J Nucl Med. 2005;46:2014-2019.
33. 18F-FDG-PET/CT with integrated full diagnostic isotropic CT imaging. Eur J Radiol. 2010;73:518-525.
34. 18F-FDG PET/CT. J Nucl Med. 2008;49:1980-1985.
35. 18F-FDG PET and 111In-granulocyte scintigraphy. Eur J Nucl Med Mol Imaging. 2004;31:622-626.
36. Kubota K, Nakamoto Y, Tamaki N, et al. FDG-PET for the diagnosis of fever of unknown origin: a Japanese multi-center study. Ann Nucl Med. 2011;25:355-364.
37. Meller J, Sahlmann CO, Lehmann K, et al. F-18-FDG hybrid camera PET in patients with postoperative fever [in German]. Nuklearmedizin. 2002;41:22-29.
38. 18F]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. Eur J Nucl Med. 2000;27:1617-1625.
39. Balink H, Collins J, Bruyn GA, Gemmel F. F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Clin Nucl Med. 2009;34:862-868.
40. Sheng JF, Sheng ZK, Shen XM, et al. Diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with fever of unknown origin. Eur J Intern Med. 2011;22:112-116.
41. Simons KS, Pickkers P, Bleeker-Rovers CP, Oyen WJ, van der Hoeven JG. F-18- fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Intensive Care Med. 2010;36:504-511.
42. 18F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia. J Nucl Med. 2010;51:1234-1240.
43. Zhao K, Dong MJ, Ruan LX, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010;39:174-180.
44. Durack DT, Street AC. Fever of unknown origin: reexamined and redefined. Curr Clin Top Infect Dis. 1991;11:35-51.
45. 18F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum. 2009;60:1193-1200.
46. Bleeker-Rovers CP, Bredie SJ, van der Meer JW, Corstens FH, Oyen WJ. F-18- fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med. 2003;61:323-329.
47. Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med. 2000;108:246-249.
48. 18F]-FDG PET/CT. Invest Radiol. 2011;46:594-599.
49. Förster S, Tato F, Weiss M, et al. Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. Vasa. 2011;40:219-227.
50. 18F-FDG PET coregistered with enhanced CT. J Nucl Med. 2005;46:917-922.
51. 18F- fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with takayasu arteritis. Arthritis Rheum. 2011;64:866-875.
52. Lee SG, Ryu JS, Kim HO, et al. Evaluation of disease activity using F-18 FDG PET-CT in patients with Takayasu arteritis. Clin Nucl Med. 2009;34:749-752.
53. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis: a controlled, blinded re-examination of routine PET scans. Clin Rheumatol. 2011;30:37-42.
54. 18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005;32:674-681.
55. 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging. 2004;31:627-634.
56. Yamashita H, Kubota K, Takahashi Y, et al. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol. December 29, 2011 [Epub ahead of print].
57. Sainaresh V, Jain Sh, Patel H, Shah P, Vanikar A, Trivedi H. Post transplant urinary tract infection in autosomal dominant polycystic kidney disease a perpetual diagnostic dilema - 18-fluorodeoxyglucose - positron emission computerized tomography - a valuable tool. Indian J Nucl Med. 2011;26:109-111.
58. Agrawal K, Bhattacharya A, Singh SK, Manohar K, Kashyap R, Mittal BR. Polycystic kidney disease: renal cyst infection detected on F-18 FDG PET/CT. Clin Nucl Med. 2011;36:1122-1123.
59. Piccoli GB, Arena V, Consiglio V, et al. Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and "cystic" kidneys: a case series. BMC Nephrol. 2011;12:48.
60. Jouret F, Lhommel R, Beguin C, et al. Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:1644-1650.
61. Jiménez-Bonilla JF, Quirce R, Calabia ER, Banzo I, Martínez-Rodríguez I, Carril JM. Hepatorenal polycystic disease and fever: diagnostic contribution of gallium citrate Ga 67 scan and fluorine F 18 FDG-PET/CT. Eur Urol. 2011;59:297-299.
62. 18F- fluorodeoxyglucose PET/CT in polycystic kidney disease. Ann Nucl Med. 2008;22:529-531.
63. Bleeker-Rovers CP, de Sévaux RG, van Hamersvelt HW, Corstens FH, Oyen WJ. Diagnosis of renal and hepatic cyst infections by 18-F- fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2003;41:E18-E21.
64. 18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2004;25:813-818.
65. Ploux S, Riviere A, Amraoui S, et al. Positron emission tomography in patients with suspected pacing system infections may play a critical role in difficult cases. Heart Rhythm. 2011;8:1478-1481.
66. Bhargava P, Kumar R, Zhuang H, Charron M, Alavi A. Catheter-related focal FDG activity on whole body PET imaging. Clin Nucl Med. 2004;29:238-242.
67. Gabaldon D, Xu Z, Sun Y, Servilla KS, Hartshorne MF, Tzamaloukas AH. Hemodialysis catheter infection with unusual presentation and grave outcome. Hemodial Int. 2011;15:568-572.
68. Costo S, Hourna E, Massetti M, Belin A, Bouvard G, Agostini D. Impact of F-18 FDG PET-CT for the diagnosis and management of infection in JARVIK 2000 device. Clin Nucl Med. 2011;36:e188-e191.
69. Singh P, Wiggins B, Sun Y, et al. Imaging of peritoneal catheter tunnel infection using positron-emission tomography. Adv Perit Dial. 2010;26:96-100.
70. 18F]fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: a preliminary prospective study. Clin Microbiol Infect. 2011;17:836-844.
71. 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:1438.
72. Sathekge M, Goethals I, Maes A, van de Wiele C. Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Mol Imaging. 2009;36:1176-1184.
73. Masekela R, Gongxeka H, Green RJ, Sathekge M. Positron emission tomography in the prediction of inflammation in children with human immunodeficiency virus related bronchiectasis. Hell J Nucl Med. 2012;15:23-27.
74. Wada T, Kubota K, Minamimoto R, et al. FDG uptake by a condylomata acuminata in an HIV-infected patient mimicked urine contamination. Clin Nucl Med. 2012;37:420-421.
75. Belkhir L, Jonckheere S, Lhommel R, Vandercam B, Yombi JC. High FDG uptake on FDG-PET scan in HIV-1 infected patient with advanced disease. Acta Clin Belg. 2011;66:419-421.
76. Liu Y. Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT. Ann Nucl Med. 2011;25:536-546.
77. 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med. 2011;52:880-885.
78. Sathekge M, Maes A, Kgomo M, Pottel H, Stolz A, Van De Wiele C. FDG uptake in lymph-nodes of HIV1 and tuberculosis patients: implications for cancer staging. Q J Nucl Med Mol Imaging. 2010;54:698-703.
79. Lucignani G, Orunesu E, Cesari M, et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging. 2009;36:640-647.
80. Barker R, Kazmi F, Stebbing J, et al. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease. Eur J Nucl Med Mol Imaging. 2009;36:648-652.
81. 18Ffluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS. 2008;22:695-700.
82. Kösters K, Bleeker-Rovers CP, van Crevel R, Oyen WJ, van der Ven AJ. Aortitis diagnosed by F-18-fluorodeoxyglucose positron emission tomography in a patient with syphilis and HIV coinfection. Infection. 2005;33:387-389.
83. Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet. 2003;362:959-961.
84. Kosterink JG. Positron emission tomography in the diagnosis and treatment management of tuberculosis. Curr Pharm Des. 2011;17:2875-2880.
85. 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging. 2008; 35:808-814.
86. Ichiya Y, Kuwabara Y, Sasaki M, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med. 1996;10:185-191.
87. Sathekge M, Maes A, Kgomo M, Stoltz A, Pottel H, Van de Wiele C. Impact of FDG PET on the management of TBC treatment: a pilot study. Nuklearmedizin. 2010;49:35-40.
88. Basu S, Chryssikos T, Houseni M, et al. Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection? Nucl Med Commun. 2007;28:465-472.
89. 18F-FDG-PET/CT imaging replaceWBC imaging in the diabetic foot? J Nucl Med. 2011;52:1012-1019.
90. Nawaz A, Torigian DA, Siegelman ES, Basu S, Chryssikos T, Alavi A. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol. 2010; 12:335-342.
91. 18F-FDG PET/CT. J Nucl Med. 2005;46:444-449.
92. 99mTc-MOAB. J Intern Med. 2008;263:99-106.
93. Chacko TK, Zhuang H, Stevenson K, Moussavian B, Alavi A. The importance of the location of fluorodeoxyglucose uptake in periprosthetic infection in painful hip prostheses. Nucl Med Commun. 2002;23:851-855.
94. Chryssikos T, Parvizi J, Ghanem E, Newberg A, Zhuang H, Alavi A. FDG-PET imaging can diagnose periprosthetic infection of the hip. Clin Orthop Relat Res. 2008;466:1338-1342.
95. 18F FDG-PET/CT in detecting hip prosthesis infection: a study in patients undergoing two-stage revision arthroplasty with an interim spacer. Q J Nucl Med Mol Imaging. 2010;54:429-435.
96. 18F-FDG PET for the diagnosis of endoprosthetic loosening and infection in hip and knee arthroplasty: results from a prospective, blinded study. BMC Musculoskelet Disord. 2006;7:20.
97. García-Barrecheguren E, Rodríguez Fraile M, Toledo Santana G, Valentí Nín JR, Richter Echevarría JA. FDG-PET: a new diagnostic approach in hip prosthetic replacement [in Spanish]. Rev Esp Med Nucl. 2007;26:208-220.
98. Gravius S, Gebhard M, Ackermann D, Büll U, Hermanns-Sachweh B, Mumme T. Nuklearmedizin. 2010;49:115-123.
99. Kobayashi N, Inaba Y, Choe H, et al. Use of F-18 fluoride PET to differentiate septic from aseptic loosening in total hip arthroplasty patients. Clin Nucl Med. 2011;36:e156-e161.
100. 99mTc-sulfur colloid marrow imaging. J Nucl Med. 2004; 45:1864-1871.
101. Love C, Pugliese PV, Afriyie MO, Tomas MB, Marwin SE, Palestro CJ. Utility of F-18 FDG imaging for diagnosing the infected joint replacement. Clin Positron Imaging. 2000;3:159.
102. 18F-FDG-PET in the diagnosis of endoprosthetic loosening of knee and hip implants. Arch Orthop Trauma Surg. 2010;130:1231-1238.
103. 18F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl Med Commun. 2002;23:645-653.
104. Mumme T, Reinartz P, Alfer J, Müller-Rath R, Buell U, Wirtz DC. Diagnostic values of positron emission tomography versus triple-phase bone scan in hip arthroplasty loosening. Arch Orthop Trauma Surg. 2005;125:322-329.
105. Pill SG, Parvizi J, Tang PH, et al. Comparison of fluorodeoxyglucose positron emission tomography and 111indium-white blood cell imaging in the diagnosis of periprosthetic infection of the hip. J Arthroplasty. 2006;21(6, suppl 2):91-97.
106. Reinartz P, Mumme T, Hermanns B, et al. Radionuclide imaging of the painful hip arthroplasty: positron-emission tomography versus triple-phase bone scanning. J Bone Joint Surg Br. 2005;87:465-470.
107. 18FDG-PET for the detection of infected hip prosthesis. Eur J Nucl Med Mol Imaging. 2003;30:705-715.
108. 99mtc-HMPAO white blood cell SPET and bone scintigraphy in the evaluation of painful total knee arthroplasties. Eur J Nucl Med. 2001;28:1496-1504.
109. 18F-FDG PET in detecting infected lower limb prosthesis implants. J Nucl Med. 2001;42:44-48.
110. Bruggink JL, Glaudemans AW, Saleem BR, et al. Accuracy of FDG-PET-CT in the diagnostic work-up of vascular prosthetic graft infection. Eur J Vasc Endovasc Surg. 2010;40:348-354.
111. Fukuchi K, Ishida Y, Higashi M, et al. Detection of aortic graft infection by fluorodeoxyglucose positron emission tomography: comparison with computed tomographic findings. J Vasc Surg. 2005;42:919-925.
112. 18F-FDG PET/CT: our experience with 96 prostheses. Eur J Nucl Med Mol Imaging. 2009;36:850-858.
113. 18F-FDG uptake in synthetic aortic vascular grafts on PET/CT in symptomatic and asymptomatic patients. J Nucl Med. 2008;49:1601-1605.
114. 18F-FDG PET/CT. J Nucl Med. 2007;48:1230-1236.
115. Spier BJ, Perlman SB, Reichelderfer M. FDG-PET in inflammatory bowel disease. Q J Nucl Med Mol Imaging. 2009;53:64-71.
116. Glaudemans AW, Maccioni F, Mansi L, Dierckx RA, Signore A. Imaging of cell trafficking in Crohn's disease. J Cell Physiol. 2010;223:562-571.
117. Kenzaka T, Shimoshikiryo M, Kitao A, Kario K, Hashimoto M. Positron emission tomography scan can be a reassuring tool to treat difficult cases of infective endocarditis. J Nucl Cardiol. 2011;18:741-743.
118. Vind SH, Hess S. Possible role of PET/CT in infective endocarditis. J Nucl Cardiol. 2010;17:516-519.
119. 18F-FDG-PET in infective endocarditis: promising role in difficult diagnosis and treatment monitoring. Hell J Nucl Med. 2009;12:165-167.
120. Product information sheet for METATRACE FDG- (fludeoxyglucose F 18 injection, USP). PETNET Project Toolkit Center Web site. Available at: http://clients.logica3.com/petnet/toolkit/website/library/Documents/04-02.pdf. Accessed September 19, 2012.
121. ICRP. Radiation dose to patients from radiopharmaceuticals: addendum 3 to ICRP Publication 53-ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2008;38:1-197.
122. 18F-FDG dose to the fetus during early pregnancy. J Nucl Med. 2010;51:803-805.
123. 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis. J Nucl Med. 2010;51:1015-1020.
124. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J. Nucl Med 1993;34:355-359.
125. Minamimoto R, Takahashi N, Inoue T. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues. Ann Nucl Med. 2007;21:217-222.
126. 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55:131-137.
127. Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F. The new EANM paediatric dosage card. EANM Dosimetry and Paediatrics Committees. Eur J Nucl Med Mol Imaging. 2007;34:796-798.
128. Lassmann M, Biassoni L, Monsieurs M, Franzius C. The new EANM paediatric dosage card: additional notes with respect to F-18. EANM Dosimetry and Paediatrics Committees. Eur J Nucl Med Mol Imaging. 2008;35:1666-1668.
129. Gelfand MJ, Parisi MT, Treves ST. Pediatric radiopharmaceutical administered doses: 2010 North American Consensus Guidelines. J Nucl Med. 2011;52:318-322.
130. 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95-99.
131. Jabour BA, Choi Y, Hoh CK, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology. 1993;186:27-35.
132. Cook GJ, Fogelman I, Maisey MN. Normal physiology and benign pathological variants of 18-fluoro-2-deoxyglucose postitron emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-314.
133. Shammas A, Lim R, Charron M. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions. Radiographics. 2009;29:1467-1486.
134. Kazama T, Swanston N, Podoloff DA, et al. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005;32:1406-1411.
135. 18F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. Eur J Nucl Med Mol Imaging. 2010;37:1181-1188.
136. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:123-129.
137. 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J Nucl Med. 2008;49:1107-1113.
138. 18F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30:730-736.
139. Russell JR, Stabin MG, Sparks RB, Watson E. Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals. Health Phys. 1997;73:756-769.
140. 18F-FDG. J Nucl Med. 2004;45:634-635.